Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000004
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 1
---
:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2025 (FY2024), as below.

1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2025

(millions JPY)

|                        |     |   Revenue |     | Operating 
    profit |     | Profit before 
  income taxes |     | Net profit attributable 
            to owners of 
             the Company |     | Basic earnings 
 per share      |
| Previous Forecast (A)* |     | 4,480,000 |     |   265,000 |     |        93,000 |     |                  68,000 |     | 43.03 JPY      |
| Revised Forecast (B)   |     | 4,590,000 |     |   344,000 |     |       162,000 |     |                 118,000 |     | 74.68 JPY      |
| Discrepancy (B-A)      |     |   110,000 |     |    79,000 |     |        69,000 |     |                  50,000 |     | ―              |
| Change %               |     |      2.5% |     |     29.8% |     |         74.2% |     |                   73.5% |     | ―              |

* Announced on October 31, 2024.

(millions JPY)

|                        |     | Core Revenue |     |      Core 
 Operating 
    Profit |     | Core EPS |
| Previous Forecast (A)* |     |    4,480,000 |     | 1,050,000 |     | 456 JPY  |
| Revised Forecast (B)   |     |    4,590,000 |     | 1,150,000 |     | 507 JPY  |
| Discrepancy (B-A)      |     |      110,000 |     |   100,000 |     | ―        |
| Change %               |     |         2.5% |     |      9.5% |     | ―        |

* Announced on October 31, 2024.

(Note) For the definition of Core financial measures, please refer to the “Definition and Explanation of Non-IFRS Measures